Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the use of PARP inhibitors within the treatment landscape for ovarian cancer.
Utilizing Clinical Pathways in Ovarian Cancer
Dr Haumschild explores considerations for safe and appropriate dosing for patients receiving PARP inhibitor therapy.
The significance of multidisciplinary teams in ovarian cancer treatment is highlighted.
Dr Haumschild discusses the substantial impact of clinical pathways in the treatment of ovarian cancer.
Dr Haumschild navigates financial considerations associated with treatment of ovarian cancer.
Quality of life and safety profiles are discussed by Ryan Haumschild, PharmD, MS, MBA.
A medical expert navigates clinical pathway considerations in the treatment of ovarian cancer.
In his closing thoughts, Dr Haumschild discusses unmet needs in the treatment landscape for ovarian cancer.
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency
2
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
3
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
4
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
5
